Integration of CK2 inhibitors in treatment of leukemias: CIGB-300 promotes activation of the tumor suppressor PTEN and abrogates PI3K-mediated downstream signaling in CLL cells. The gene discussed is PTEN; the disease is B-cell chronic lymphocytic leukemia.